Model-Based Meta-Analysis of IL-17 A Inhibitors for Moderate-to-Severe Plaque Psoriasis: Establishing Exposure-Response Relationships to Inform Targeted Drug Development.

Yixiao Liu, Xiaoya Chen, Ling Xu, Qingshan Zheng, Lujin Li

Abstract readMeta-AnalysisReview

In one paragraph

Synthesis in Clinical reviews in allergy & immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Clove (Frontiers in pharmacology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yixiao Liu *Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Shanghai, 201203, China.

Xiaoya Chen *Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Shanghai, 201203, China.

Ling XuCenter for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Shanghai, 201203, China.

Qingshan ZhengCenter for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Shanghai, 201203, China. qingshan.zheng@drugchina.net.

Lujin LiCenter for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Shanghai, 201203, China. lilujin666@163.com.

Funding

China national key research and development program 2022YFC3502000National Key R&D Program of China SQ2024YFC3500039National Natural Science Funds of China 82174229Shanghai S&T Innovation Plan 17401970900

6 · The paper itself

Abstract

This study aimed to establish an exposure-response model for IL-17 A inhibitors to predict the clinical efficacy of novel agents based on in vitro potency and pharmacokinetic parameters, guiding the development of new IL-17 A-targeting therapies. A systematic literature search was conducted in PubMed, Cochrane Library, and Embase to identify randomized controlled trials of three FDA-approved IL-17 A inhibitors: secukinumab, ixekizumab, and bimekizumab. Primary endpoints included PASI 75 and PASI 90. Pharmacokinetic parameters were extracted from FDA and EMA review documents, while the half-maximal inhibitory concentration (IC

Indexed as

Interleukin-17PsoriasisAntibodies, Monoclonal, HumanizedDose-Response Relationship, DrugDrug DevelopmentHumansRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment OutcomeAntibodies, Monoclonal, HumanizedbimekizumabIL17A protein, humanInterleukin-17ixekizumabsecukinumabExposure-response modelIL-17A inhibitorModel-based meta-analysisModerate-to-severe plaque psoriasisPsoriasis area and severity index

Identifiers

PMID41543629

DOI10.1007/s12016-025-09123-5

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.